BioVie (BIVI) Competitors $6.67 -0.30 (-4.36%) Closing price 03:58 PM EasternExtended Trading$6.85 +0.18 (+2.76%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BIVI vs. APLT, RPTX, CRVO, ASRT, STRO, HOWL, SCLX, IKNA, BRNS, and MNOVShould you be buying BioVie stock or one of its competitors? The main competitors of BioVie include Applied Therapeutics (APLT), Repare Therapeutics (RPTX), CervoMed (CRVO), Assertio (ASRT), Sutro Biopharma (STRO), Werewolf Therapeutics (HOWL), Scilex (SCLX), Ikena Oncology (IKNA), Barinthus Biotherapeutics (BRNS), and MediciNova (MNOV). These companies are all part of the "pharmaceutical products" industry. BioVie vs. Its Competitors Applied Therapeutics Repare Therapeutics CervoMed Assertio Sutro Biopharma Werewolf Therapeutics Scilex Ikena Oncology Barinthus Biotherapeutics MediciNova Applied Therapeutics (NASDAQ:APLT) and BioVie (NASDAQ:BIVI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, media sentiment and dividends. Does the media prefer APLT or BIVI? In the previous week, Applied Therapeutics and Applied Therapeutics both had 5 articles in the media. Applied Therapeutics' average media sentiment score of 0.79 beat BioVie's score of 0.61 indicating that Applied Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Applied Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioVie 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders have more ownership in APLT or BIVI? 98.3% of Applied Therapeutics shares are owned by institutional investors. Comparatively, 4.6% of BioVie shares are owned by institutional investors. 1.6% of Applied Therapeutics shares are owned by insiders. Comparatively, 2.4% of BioVie shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is APLT or BIVI more profitable? BioVie's return on equity of -100.88% beat Applied Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Applied TherapeuticsN/A -184.67% -84.02% BioVie N/A -100.88%-78.49% Which has more risk & volatility, APLT or BIVI? Applied Therapeutics has a beta of 1.82, meaning that its stock price is 82% more volatile than the S&P 500. Comparatively, BioVie has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500. Which has higher valuation & earnings, APLT or BIVI? BioVie has lower revenue, but higher earnings than Applied Therapeutics. Applied Therapeutics is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioApplied Therapeutics$460K132.96-$105.62M-$0.43-1.00BioVieN/AN/A-$32.12M-$79.10-0.08 Do analysts recommend APLT or BIVI? Applied Therapeutics presently has a consensus price target of $6.10, indicating a potential upside of 1,312.04%. Given Applied Therapeutics' higher possible upside, analysts plainly believe Applied Therapeutics is more favorable than BioVie.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Applied Therapeutics 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50BioVie 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 SummaryApplied Therapeutics and BioVie tied by winning 7 of the 14 factors compared between the two stocks. Get BioVie News Delivered to You Automatically Sign up to receive the latest news and ratings for BIVI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BIVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIVI vs. The Competition Export to ExcelMetricBioVieMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.40M$2.46B$5.59B$9.53BDividend YieldN/A1.77%4.71%4.03%P/E Ratio-0.089.4927.9619.93Price / SalesN/A427.91389.5465.88Price / CashN/A165.5736.3258.75Price / Book0.264.968.375.77Net Income-$32.12M$31.62M$3.25B$259.10M7 Day Performance-19.10%-3.27%-2.50%-3.41%1 Month Performance-27.94%9.78%7.98%8.53%1 Year Performance73.55%-5.75%34.65%15.75% BioVie Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIVIBioVie0.91 of 5 stars$6.67-4.4%N/A+70.0%$12.40MN/A-0.0810APLTApplied Therapeutics4.2934 of 5 stars$0.46-0.4%$6.10+1,226.1%-91.2%$65.39M$460K-1.0730News CoverageUpcoming EarningsRPTXRepare Therapeutics2.8084 of 5 stars$1.50-0.7%$4.50+200.0%-61.7%$64.77M$53.48M-0.50180Upcoming EarningsCRVOCervoMed3.2249 of 5 stars$8.43+13.8%$22.57+167.8%-41.6%$64.49M$9.74M-3.874News CoverageAnalyst ForecastGap UpASRTAssertio2.1247 of 5 stars$0.70+3.3%$2.75+295.7%-51.3%$64.46M$124.96M-2.1720News CoveragePositive NewsUpcoming EarningsSTROSutro Biopharma4.2165 of 5 stars$0.80+5.3%$6.11+664.3%-80.4%$64.19M$62.04M-0.27240HOWLWerewolf Therapeutics4.0182 of 5 stars$1.40-0.7%$8.33+495.2%-51.5%$63.27M$1.88M-0.8440News CoverageSCLXScilex2.5276 of 5 stars$8.60-2.9%$455.00+5,190.7%-71.7%$61.59M$56.59M-0.3080IKNAIkena OncologyN/A$1.27flat$3.00+136.2%N/A$61.29M$9.16M-1.4870Earnings ReportStock SplitHigh Trading VolumeBRNSBarinthus Biotherapeutics3.4714 of 5 stars$1.97+31.5%$6.25+217.3%+3.4%$60.41M$14.97M-1.20107Positive NewsUpcoming EarningsHigh Trading VolumeMNOVMediciNova1.6011 of 5 stars$1.26+2.4%$7.00+455.6%+2.3%$60.33M$1M-5.4810Upcoming Earnings Related Companies and Tools Related Companies Applied Therapeutics Competitors Repare Therapeutics Competitors CervoMed Competitors Assertio Competitors Sutro Biopharma Competitors Werewolf Therapeutics Competitors Scilex Competitors Ikena Oncology Competitors Barinthus Biotherapeutics Competitors MediciNova Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BIVI) was last updated on 7/30/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredStrange Investment Secret Predicts Market's Next Move?A strange market signal discovered before the Great Depression has predicted nearly every major financial even...Weiss Ratings | SponsoredI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioVie Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioVie With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
